These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8683875)

  • 21. Triple-head SPECT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG): initial evaluation in oncology and comparison with FDG PET.
    Macfarlane DJ; Cotton L; Ackermann RJ; Minn H; Ficaro EP; Shreve PD; Wahl RL
    Radiology; 1995 Feb; 194(2):425-9. PubMed ID: 7824722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients.
    Schöder H; Erdi YE; Chao K; Gonen M; Larson SM; Yeung HW
    J Nucl Med; 2004 Apr; 45(4):559-66. PubMed ID: 15073250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET FDG studies in oncology.
    Hawkins RA; Hoh CK
    Nucl Med Biol; 1994 Jul; 21(5):739-47. PubMed ID: 9241650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.
    Gritters LS; Francis IR; Zasadny KR; Wahl RL
    J Nucl Med; 1993 Sep; 34(9):1420-7. PubMed ID: 8355058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer.
    Higashi K; Nishikawa T; Seki H; Oguchi M; Nambu Y; Ueda Y; Yuasa K; Tonami H; Okimura T; Yamamoto I
    J Nucl Med; 1998 Jan; 39(1):9-15. PubMed ID: 9443730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the performance of a whole-body positron imaging system with attenuation correction.
    Ota T; Ito K; Tadokoro M; Kato T; Nishino M; Amano M; Ishigaki T
    Radiat Med; 1995; 13(3):121-8. PubMed ID: 7569003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose.
    Steinert HC; Huch Böni RA; Buck A; Böni R; Berthold T; Marincek B; Burg G; von Schulthess GK
    Radiology; 1995 Jun; 195(3):705-9. PubMed ID: 7753998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
    Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
    J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations.
    Engel H; Steinert H; Buck A; Berthold T; Huch Böni RA; von Schulthess GK
    J Nucl Med; 1996 Mar; 37(3):441-6. PubMed ID: 8772641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
    Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
    Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of whole-body positron emission tomography in the imaging of esophageal cancer: report of a case.
    Yasuda S; Raja S; Hubner KF
    Surg Today; 1995; 25(3):261-4. PubMed ID: 7640457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of FDG PET in patients with cervical cancer.
    Sugawara Y; Eisbruch A; Kosuda S; Recker BE; Kison PV; Wahl RL
    J Nucl Med; 1999 Jul; 40(7):1125-31. PubMed ID: 10405131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.
    Shreve PD; Grossman HB; Gross MD; Wahl RL
    Radiology; 1996 Jun; 199(3):751-6. PubMed ID: 8638000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast imaging with fluorine-18-FDG PET: quantitative image analysis.
    Avril N; Bense S; Ziegler SI; Dose J; Weber W; Laubenbacher C; Römer W; Jänicke F; Schwaiger M
    J Nucl Med; 1997 Aug; 38(8):1186-91. PubMed ID: 9255146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
    Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
    Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
    Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
    Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parametric images of myocardial metabolic rate of glucose generated from dynamic cardiac PET and 2-[18F]fluoro-2-deoxy-d-glucose studies.
    Choi Y; Hawkins RA; Huang SC; Gambhir SS; Brunken RC; Phelps ME; Schelbert HR
    J Nucl Med; 1991 Apr; 32(4):733-8. PubMed ID: 2013815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.
    Shulkin BL; Mitchell DS; Ungar DR; Prakash D; Dole MG; Castle VP; Hernandez RJ; Koeppe RA; Hutchinson RJ
    Radiology; 1995 Feb; 194(2):495-500. PubMed ID: 7824731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
    Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
    J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.